Applied UV to Host First Quarter 2022 Conference Call on May 24, 2022
18 May 2022 - 10:00PM
Business Wire
Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the
“Company”), a pathogen elimination technology company that applies
the power of narrow-range ultraviolet light (“UVC”) for surface
areas and catalytic bioconversion technology for air purification
to destroy pathogens safely, thoroughly, and automatically,
announced that the Company will be hosting an investor conference
call and live webcast on Tuesday, May 24, 2022 at 9:00 am ET to
review its financial results. First quarter 2022 financial results
will be released after market close on Monday, May 23rd and will be
available through the Investor Relations section of the company's
website at https://irdirect.net/AUVI.
Conference Call/Webcast Information
Applied UV's management team will host an investor conference
call and live webcast on May 24, 2022, at 9:00 am ET. Investors can
access the live webcast via a link on Applied UV's web site at
https://www.webcaster4.com/Webcast/Page/2626/45615. For those
planning to participate on the call, please dial +1-877-545-0320
(for domestic calls), or +1-973-528-0002 (for international calls),
passcode 867374. A replay of the conference call will be available
online on the Applied UV web site, and a dial-in replay will be
available for one week following the call at +1-877-481-4010 (for
domestic calls) or +1-919-882-2331 (for international calls),
replay passcode 45615.
About Applied UV
Applied UV is focused on the development and acquisition of
technology that address infection control in the healthcare,
hospitality, commercial and municipal markets. The Company has two
wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and
Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for
Data Driven Disinfection™ applies the power of ultraviolet light
(UVC) to destroy pathogens safely, thoroughly, and automatically,
addressing the challenge of healthcare-acquired infections
("HAIs"). Targeted for use in facilities that have high customer
turnover such as hospitals, hotels, commercial facilities, and
other public spaces, the Company’s Lumicide™ platform uses UVC LEDs
in several patented designs for infection control in and around
high-traffic areas, including sinks and restrooms, killing
bacteria, viruses, and other pathogens residing on hard surfaces
within devices’ proximity. The Company’s patented in-drain
disinfection device, Lumicide Drain, is the only product on the
market that addresses this critical pathogen intensive location.
SteriLumen’s Airocide® air purification devices are research
backed, clinically proven, and developed for NASA with assistance
from the University of Wisconsin. Airocide® is listed as an FDA
Class II Medical device, utilizes a proprietary photocatalytic
(PCO) bioconversion technology that draws air into a reaction
chamber that converts damaging molds, microorganisms, dangerous
airborne pathogens, destructive VOCs, allergens, odors and
biological gasses into harmless water vapor and green carbon
dioxide without producing ozone or other harmful byproducts.
Airocide® applications include healthcare, hospitality, grocery
chains, wine making facilities, commercial real estate, schools,
dental offices, post-harvest, grocery, cannabis facilities and
homes. For more information about Applied UV, Inc., and its
subsidiaries, please visit the following website:
https://www.applieduvinc.com/.
Forward-Looking Statements
The information contained herein may contain “forward‐looking
statements.” Forward‐looking statements reflect the current view
about future events. When used in this press release, the words
“anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,”
“plan,” or the negative of these terms and similar expressions, as
they relate to us or our management, identify forward‐looking
statements. Such statements include, but are not limited to,
statements contained in this press release relating to the view of
management of Applied UV concerning its business strategy, future
operating results and liquidity and capital resources outlook.
Forward‐looking statements are based on the Company’s current
expectations and assumptions regarding its business, the economy
and other future conditions. Because forward–looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict.
The Company’s actual results may differ materially from those
contemplated by the forward‐looking statements. They are neither
statements of historical fact nor guarantees of assurance of future
performance. We caution you therefore against relying on any of
these forward‐looking statements. Factors or events that could
cause the Company’s actual results to differ may emerge from time
to time, and it is not possible for the Company to predict all of
them. The Company cannot guarantee future results, levels of
activity, performance, or achievements. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward‐looking
statements to conform these statements to actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005245/en/
For additional Company Information: Applied UV Inc. John
F. Andrews CEO/Director john.andrews@applieduvinc.com
Contact: Brett Maas, Managing Principal Hayden IR
brett@haydenir.com (646) 536-7331
Applied UV (NASDAQ:AUVI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Applied UV (NASDAQ:AUVI)
Historical Stock Chart
From Mar 2023 to Mar 2024